GenVec
 |
|
| Type | Public company |
|---|---|
| Traded as | NASDAQ: GNVC |
| Industry | Pharmaceuticals |
| Headquarters | Gaithersburg, Maryland, United States |
| Key people | Cynthia Collins, President and CEO Douglas J. Swirsky, Senior Vice President and Chief Financial Officer |
| Products | TNFeradeTM Phase III |
| Revenue | $13.9 million (2009) |
| Net income |  $18.4 million (2009) |
| Employees | 85 |
| Website | www.genvec.com |
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. GenVec currently has a collaboration with Novartis AG to develop treatments for hearing loss and balance disorders worldwide. GenVec is also working with companies and organizations such as Merial, and the U.S. Government on vaccine development. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) gave conditional approval to GenVec's foot-and-mouth disease (FMD) vaccine in the middle of 2012. This was a significant achievement as it marked GenVec's first approved product.
[edit] TNFerade
TNFerade (the Company's previous lead product candidate) failed a phase III trial for pancreatic cancer. There was an 8% reduction in risk of death but it was not statistically significant.[1] TNFerade is “an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNFα), an immune system protein, for direct injection into tumors”.[1]
[edit] References
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
